Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology

Sudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has b...

ver descrição completa

Detalhes bibliográficos
Autores: Kaski JP, Kammeraad JAE, Blom NA, Happonen JM, Janousek J, Klaassen S, Limongelli G, Östman-Smith I, Sarquella Brugada G, Ziolkowska L
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p23412
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=23412
Access Level:acceso abierto
Palavra-chave:Hypertrophic cardiomyopathy
sudden cardiac death
risk factor
implantable defibrillator
child
id ES_482c8d02a0fc3a4e4ba6954a7083dc77
oai_identifier_str oai:fsjd.fundanetsuite.com:p23412
network_acronym_str ES
network_name_str España
repository_id_str
spelling Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and ElectrophysiologyKaski JPKammeraad JAEBlom NAHapponen JMJanousek JKlaassen SLimongelli GÖstman-Smith ISarquella Brugada GZiolkowska LHypertrophic cardiomyopathysudden cardiac deathrisk factorimplantable defibrillatorchildSudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has been shown to be effective at terminating malignant ventricular arrhythmias in children with hypertrophic cardiomyopathy but can be associated with substantial morbidity. Accurate identification of those children at highest risk who would benefit most from implantable cardioverter-defibrillator implantation while minimising the risk of complications is, therefore, essential. This position statement, on behalf of the Association for European Paediatric and Congenital Cardiology (AEPC), reviews the currently available data on established and proposed risk factors for sudden cardiac death in childhood-onset hypertrophic cardiomyopathy and current approaches for risk stratification in this population. It also provides guidance on identification of individuals at risk of sudden cardiac death and optimal management of implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.CAMBRIDGE UNIV PRESS2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=23412CARDIOLOGY IN THE YOUNGISSN: 10479511ISSNe: 14671107reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p234122026-05-27T12:37:41Z
dc.title.none.fl_str_mv Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
title Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
spellingShingle Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
Kaski JP
Hypertrophic cardiomyopathy
sudden cardiac death
risk factor
implantable defibrillator
child
title_short Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
title_full Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
title_fullStr Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
title_full_unstemmed Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
title_sort Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology
dc.creator.none.fl_str_mv Kaski JP
Kammeraad JAE
Blom NA
Happonen JM
Janousek J
Klaassen S
Limongelli G
Östman-Smith I
Sarquella Brugada G
Ziolkowska L
author Kaski JP
author_facet Kaski JP
Kammeraad JAE
Blom NA
Happonen JM
Janousek J
Klaassen S
Limongelli G
Östman-Smith I
Sarquella Brugada G
Ziolkowska L
author_role author
author2 Kammeraad JAE
Blom NA
Happonen JM
Janousek J
Klaassen S
Limongelli G
Östman-Smith I
Sarquella Brugada G
Ziolkowska L
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hypertrophic cardiomyopathy
sudden cardiac death
risk factor
implantable defibrillator
child
topic Hypertrophic cardiomyopathy
sudden cardiac death
risk factor
implantable defibrillator
child
description Sudden cardiac death is the most common mode of death during childhood and adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest risk is a major aspect of clinical care. The mainstay of preventative therapy is the implantable cardioverter-defibrillator, which has been shown to be effective at terminating malignant ventricular arrhythmias in children with hypertrophic cardiomyopathy but can be associated with substantial morbidity. Accurate identification of those children at highest risk who would benefit most from implantable cardioverter-defibrillator implantation while minimising the risk of complications is, therefore, essential. This position statement, on behalf of the Association for European Paediatric and Congenital Cardiology (AEPC), reviews the currently available data on established and proposed risk factors for sudden cardiac death in childhood-onset hypertrophic cardiomyopathy and current approaches for risk stratification in this population. It also provides guidance on identification of individuals at risk of sudden cardiac death and optimal management of implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=23412
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=23412
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv CAMBRIDGE UNIV PRESS
publisher.none.fl_str_mv CAMBRIDGE UNIV PRESS
dc.source.none.fl_str_mv CARDIOLOGY IN THE YOUNG
ISSN: 10479511
ISSNe: 14671107
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407342932525056
score 15.812429

Registos relacionados